Latest & greatest articles for osteoarthritis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on osteoarthritis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on osteoarthritis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for osteoarthritis

341. Intra-articular injection of cross-linked hyaluronans for treatment of shoulder osteoarthritis

of cross-linked hyaluronans for treatment of shoulder osteoarthritis. Lansdale: HAYES, Inc.. Healthcare Technology Brief Publication. 2014 Authors' conclusions Osteoarthritis (OA) is a degenerative disease of the joints that leads to pain and disability. OA of the shoulder is the result of deterioration of the articular surface of the humeral head and glenoid, specifically, degeneration of cartilage and narrowing of the glenohumeral joint space. There are medical and surgical treatment options (...) for shoulder OA. First-line therapy is conservative, consisting of nonsteroidal anti-inflammatory drugs, physical therapy, corticosteroids, activity modification, and viscosupplementation. If symptoms are severe and disabling and unresponsive to medical therapy, the patient may require arthroscopy or partial or total shoulder joint replacement. Final publication URL The report may be purchased from: Indexing Status Subject indexing assigned by CRD MeSH Hyaluronic Acids; Injections, Intra-Articular

2014 Health Technology Assessment (HTA) Database.

342. Intra-articular injection of non?cross-linked sodium hyaluronate for treatment of shoulder osteoarthritis

. Citation Intra-articular injection of non–cross-linked sodium hyaluronate for treatment of shoulder osteoarthritis. Lansdale: HAYES, Inc.. Healthcare Technology Brief Publication. 2014 Authors' conclusions Osteoarthritis (OA) is a degenerative disease of the joints that leads to pain and disability. OA of the shoulder is the result of deterioration of the articular surface of the humeral head and glenoid, specifically, degeneration of cartilage and narrowing of the glenohumeral joint space (...) . There are medical and surgical treatment options for shoulder OA. First-line therapy is conservative consisting of nonsteroidal anti-inflammatory drugs, physical therapy, corticosteroids, activity modification, and viscosupplementation. If symptoms are severe and disabling and unresponsive to medical therapy, the patient may require arthroscopy or partial or total shoulder joint replacement. Final publication URL The report may be purchased from: Indexing Status Subject indexing assigned by CRD MeSH Humans

2014 Health Technology Assessment (HTA) Database.

343. Preoperative physical therapy for severe osteoarthritis of the hip

. 2014 Authors' objectives Physical therapy may be beneficial both before and after joint replacement surgery in patients with severe osteoarthritis (OA). In general, the goal of physical therapy in patients with OA is to increase function and physical activity despite pain and stiffness. Perioperative goals include faster recovery time, shorter hospital length of stay (LOS), and increased range of motion and function. Final publication URL The report may be purchased from: Indexing Status Subject (...) Preoperative physical therapy for severe osteoarthritis of the hip Preoperative physical therapy for severe osteoarthritis of the hip Preoperative physical therapy for severe osteoarthritis of the hip Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Preoperative physical therapy for severe osteoarthritis of the hip. Lansdale: HAYES, Inc.. Directory Publication

2014 Health Technology Assessment (HTA) Database.

344. Whole-body vibration and benefits for people with osteoarthritis: A systematic review Full Text available with Trip Pro

to treat patients with osteoarthritis (OA). The purpose of this study was to systematically review published research concerning the use of WBV in people with OA. In PubMed and Scopus, the number of publications (NP) is respectively to the keywords arthrosis, 289,586 and 10,569, osteoarthrosis, 299,158 and 3,952, arthritis, 251,453 and 236,849 and osteoarthritis, 56,323 and 80,008. Putting together the information found in the analyzed 4 papers, the numbers of subjects were ranging from 15 to 52 (...) ) to evaluate the effects promoted by the exercises due to the WBV. In conclusion, these studies indicate that the WBV could bring some benefits to patients with OA. Key words: Osteoarthrosis, arthrosis, arthritis, PubMed, Scopus, whole body vibration, oscillating/vibratory platform. Abbreviation OA, Osteoarthritis; ECM, cartilaginous extracellular matrix; NP, number of publications; NSAIDs, nonsteroidal antiinflammatory drugs; ROM, range of motion; WBV, whole body vibration; WBVT, whole body vibration

2014 International Journal of Medicine and Medical Sciences

345. Flexea (Glucosamine (hydrochloride)) - mild to moderate osteoarthritis of the knee

deviation: 5.0]; - known diagnoses were knee arthritis (79.4%), hip arthritis (16.4%) both (4.3%); - osteoarthritis present for 5 years (30.3%) - median number of pain flare-ups in the past 6 months (2.0 [range: 0.0 - 12.0]; - mean pain score (measured from 0 to 10 on the VAS) 5.6 [standard deviation: 1.8]; - disability (Lequesne algofunctional index) significant to very significant (35.3%), unbearable (18.8%); - main co-morbidities musculo-skeletal disorders (58.9%), cardiovascular disease (57.2 (...) and joint function, the Committee believed that the potential benefit of these treatments, in particular glucosamine, would reside in a possible reduction of NSAID consumption. Its favourable opinion for continued listing or inclusion of all delayed-effect symptomatic treatments for osteoarthritis depended on setting up and conducting a study, within two years after marketing (deadline of 30 June 2013), to show their impact in terms of reducing NSAID consumption. To meet the Transparency Committee's

2014 Haute Autorite de sante

346. Flector (diclofenac epolamine) - short-term symptomatic treatment of acute episodes of: extra-articular rheumatism such as scapulohumeral periarthritis, tendonitis, bursitis; microcrystalline arthritis; osteoarthritis etc

with analgesic, antipyretic, anti-inflammatory and short-term antiplatelet properties. These properties are related to the inhibition of prostaglandin synthesis. The proprietary medicinal products affected by the re-assessment are indicated to relieve pain of varying severity and inflammation in a wide range of conditions, particularly arthritic diseases (such as rheumatoid arthritis, osteoarthritis, ankylosing spondylitis and acute gout), acute musculoskeletal disorders (such as periarthritis, tendonitis (...) treatment: - chronic inflammatory rheumatic diseases, particularly rheumatoid arthritis, ankylosing spondylitis or related syndromes such as Reiter’s syndrome and psoriatic arthritis; - some painful and disabling forms of osteoarthritis. Short-term symptomatic treatment of acute episodes of: - extra-articular rheumatism (acute shoulder pain, tendonitis, bursitis); - microcrystalline arthritis; - osteoarthritis; - lumbar pain and severe radicular pain. Treatment of primary dysmenorrhoea, after

2014 Haute Autorite de sante

347. Voltaflex (Glucosamine (hydrochloride)) - mild to moderate osteoarthritis of the knee

Voltaflex (Glucosamine (hydrochloride)) - mild to moderate osteoarthritis of the knee HAS - Medical, Economic and Public Health Assessment Division 1/8 The legally binding text is the original French version TRANSPARENCY C OMMITTEE Opinion 20 November 2013 VOLTAFLEX 625 mg, film-coated tablet B/60 tablets (CIP: 34009 384 573 2) Applicant: NOVARTIS SANTÉ FAMILIALE S.A.S. INN Glucosamine (hydrochloride) ATC code (2012) M01AX05 (other non-steroidal anti-rheumatic anti-inflammatory drugs) Reason (...) for the review Re-assessment of the actual benefit pursuant to the findings of the Transparency Committee in its opinion of 10 March 2010. List(s) concerned National Health Insurance (French Social Security Code L.162-17) Indication(s) concerned "Relief of symptoms in mild to moderate osteoarthritis of the knee." HAS - Medical, Economic and Public Health Assessment Division 2/8 Actual Benefit Insufficient Actual Benefit Therapeutic Use Due to the very modest efficacy on pain and functional disability

2014 Haute Autorite de sante

348. Dolenio (Glucosamine (sulfate)) - mild to moderate osteoarthritis of the knee

- 36]; - among the 15 patients who provided information on the location of the arthritis, the majority reported the knee as the main joint affected by arthritis (11/15) and also reported at least one other secondary arthritis location; - the median delay between the onset of osteoarthritis reported by the patient and prescription of DOLENIO was 21 months [extremes: 2 - 343]; - the median pain score reported by the patient for the month of inclusion (score from 0 to 10) was 6.5 [extremes: 0 - 9 (...) of symptoms related to mild to moderate osteoarthritis of the knee): DOLENIO, FLEXEA, OSAFLEXAN, STRUCTOFLEX and VOLTAFLEX. Due to their low efficacy on pain and joint function, the Committee believed that the potential benefit of these treatments, in particular glucosamine, would reside in a possible reduction of NSAID consumption. Its favourable opinion for continued listing or inclusion of all delayed-effect symptomatic treatments for osteoarthritis depended on setting up and conducting a study, within

2014 Haute Autorite de sante

349. Structoflex (Glucosamine (hydrochloride)) - mild to moderate osteoarthritis of the knee

symptomatic treatments with a similar indication (relief of symptoms related to mild to moderate osteoarthritis of the knee): DOLENIO, FLEXEA, OSAFLEXAN, STRUCTOFLEX and VOLTAFLEX. Due to their low efficacy on pain and joint function, the Committee believed that the potential benefit of these treatments, in particular glucosamine-based medicines, would reside in a possible reduction of NSAID consumption. Its favourable opinion for continued listing or inclusion of these proprietary medicinal products (...) depended on setting up and conducting a study, within two years after marketing (deadline of 30 June 2013), to show their impact in terms of reducing NSAID consumption. To meet the Transparency Committee's request dated on 13 January 2010, Pierre Fabre Médicaments participated in the PEGASE study. As a reminder, PEGASE is a cohort study of patients with knee or hip arthritis, treated or not treated by delayed-effect symptomatic osteoarthritis medicines including glucosamine-based medicines, which aimed

2014 Haute Autorite de sante

350. Viscosupplementation for the treatment of osteoarthritis of the knee: clinical effectiveness and guidelines

Viscosupplementation for the treatment of osteoarthritis of the knee: clinical effectiveness and guidelines Viscosupplementation for the treatment of osteoarthritis of the knee: clinical effectiveness and guidelines Viscosupplementation for the treatment of osteoarthritis of the knee: clinical effectiveness and guidelines CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has (...) been made for the HTA database. Citation CADTH. Viscosupplementation for the treatment of osteoarthritis of the knee: clinical effectiveness and guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response - Summary of Abstracts. 2014 Authors' conclusions Nine systematic reviews and eight evidence-based guidelines were identified regarding viscosupplementation for the treatment of patients with osteoarthritis of the knee. Final publication URL Indexing Status

2014 Health Technology Assessment (HTA) Database.

351. Altim (Cortivazol) - arthritis, osteoarthritis, tendinitis, bursitis, talalgia, carpal tunnel syndrome, Dupuytren's contracture, radiculalgia

: - In intra-articular injection: inflammatory arthritis, advanced osteoarthritis. - In periarticular injection: tendinitis, bursitis. - In injection of soft tissue: talalgia, carpal tunnel syndrome, Dupuytren's contracture. - In epidural injection: radiculalgia" HAS - Medical, Economic and Public Health Assessment Division 2/14 Actual Benefit The Committee considers that the actual benefit of ALTIM remains substantial in rheumatological diseases: - In intra-articular injection: inflammatory arthritis (...) . This product is indicated in rheumatological diseases: - In intra-articular injection: inflammatory arthritis, advanced osteoarthritis. - In periarticular injection: tendinitis, bursitis. - In injection of soft tissue: talalgia, carpal tunnel syndrome, Dupuytren's contracture. - In epidural injection: radiculalgia" HAS - Medical, Economic and Public Health Assessment Division 4/14 03.2 Dosage Equivalent anti-inflammatory (equal potency) doses for 5 mg prednisone = 0.3 mg cortivazol. LOCAL ADMINISTRATION

2014 Haute Autorite de sante

352. Osaflexan (Glucosamine (sulfate)) - mild to moderate osteoarthritis of the knee

arthritis (16.4%) both (4.3%); - osteoarthritis present for 5 years (30.3%) - median number of pain flare-ups in the past 6 months 2.0 [range: 0.0 - 12.0]; - mean pain score (measured from 0 to 10 on the VAS) 5.6 [standard deviation: 1.8]; - disability (Lequesne algofunctional index) significant to very significant (35.3%), unbearable (18.8%); - main co-morbidities musculo-skeletal disorders (58.9%), cardiovascular disease (57.2%), other osteoarthritis locations (42.7%), endocrine (32.2 (...) , ZONDAR, CHONDROSULF and PIASCLEDINE) and, in 2009-2010, examined the various applications for inclusion of glucosamine-based proprietary medicinal products and other delayed-effect symptomatic treatments with a similar indication (relief of symptoms related to mild to moderate osteoarthritis of the knee): DOLENIO, FLEXEA, OSAFLEXAN, STRUCTOFLEX and VOLTAFLEX. Due to their low efficacy on pain and joint function, the Committee believed that the potential benefit of these treatments, in particular

2014 Haute Autorite de sante

353. 45-day mortality after 467 779 knee replacements for osteoarthritis from the National Joint Registry for England and Wales: an observational study. (Abstract)

45-day mortality after 467 779 knee replacements for osteoarthritis from the National Joint Registry for England and Wales: an observational study. Understanding the risk factors for early death after knee replacement could help to reduce the risk of mortality after this procedure. We assessed secular trends in death within 45 days of knee replacement for osteoarthritis in England and Wales, with the aim of investigating whether any change that we recorded could be explained by alterations (...) in modifiable perioperative factors.We took data for knee replacements done for osteoarthritis in England and Wales between April 1, 2003, and Dec 31, 2011, from the National Joint Registry for England and Wales. Patient identifiers were used to link these data to the national mortality database and the Hospital Episode Statistics database to obtain details of death, sociodemographics, and comorbidity. We assessed mortality within 45 days by Kaplan-Meier analysis and assessed the role of patient

2014 Lancet

354. Prolotherapy: A nontraditional approach to knee osteoarthritis

for patients with knee osteoarthritis (OA) that does not respond to conventional therapies. URI Part of Citation Journal of Family Practice, 63(4) 2014: 206-208 Rights OpenAccess. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License. Collections hosted by hosted by (...) Prolotherapy: A nontraditional approach to knee osteoarthritis Prolotherapy: A nontraditional approach to knee osteoarthritis Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Prolotherapy: A nontraditional approach to knee osteoarthritis View/ Open Date 2014-04 Format Metadata Abstract Recommend prolotherapy

2014 PURLS

355. Osteoarthritis. (Abstract)

Osteoarthritis. 24979462 2014 08 19 2015 01 26 1539-3704 161 1 2014 Jul 01 Annals of internal medicine Ann. Intern. Med. In the clinic. Osteoarthritis. ITC1-16 10.7326/0003-4819-161-1-201407010-01001 Gelber Allan C AC eng Journal Article Review United States Ann Intern Med 0372351 0003-4819 0 Analgesics AIM IM Ann Intern Med. 2014 Jul 1;161(1):ITC1-17 Ann Intern Med. 2014 Aug 19;161(4):308 Analgesics therapeutic use Diagnosis, Differential Humans Orthopedic Equipment Osteoarthritis diagnosis

2014 Annals of Internal Medicine

356. Osteoarthritis of the knee: avoid intra-articular hyaluronic acid injections

Osteoarthritis of the knee: avoid intra-articular hyaluronic acid injections Prescrire IN ENGLISH - Spotlight ''Osteoarthritis of the knee: avoid intra-articular hyaluronic acid injections '', 1 October 2013 {1} {1} {1} | | > > > Osteoarthritis of the knee: avoid intra-articular hyaluronic acid injections Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  (...) Spotlight Osteoarthritis of the knee: avoid intra-articular hyaluronic acid injections At best, intra-articular hyaluronic acid injections give modest relief to patients suffering knee osteoarthritis pain, at the price of local reactions and sometimes severe adverse effects. In patients suffering knee osteoarthritis pain, above all treatment involves physical exercises and analgesics, chiefly paracetamol. Intra-articular hyaluronic acid injections are sometimes offered, but there is no proof

2014 Prescrire

357. Prioritization of Patient-Centered Comparative Effectiveness Research for Osteoarthritis. Full Text available with Trip Pro

Prioritization of Patient-Centered Comparative Effectiveness Research for Osteoarthritis. Osteoarthritis is a leading cause of disability in the United States. This article describes a prioritized research agenda about osteoarthritis management developed for the Patient-Centered Outcomes Research Institute. Evidence gaps were identified by reviewing existing literature and engaging diverse stakeholders to expand and refine gaps. Stakeholders ranked evidence gaps by importance from

2014 Annals of Internal Medicine

358. Viscosupplementation for the Treatment of Osteoarthritis of the Knee

trials were placed in the appendix and non- randomized studies were not included. OVERALL SUMMARY OF FINDINGS Of the nine systematic reviews (SR) identified, 1-9 five SRs 2,4-5,8-9 indicated some benefit regarding the use of intra-articular hyaluronic acid (IAHA) for the treatment of knee osteoarthritis (OA), whereas the other four SRs 1,3,6-7 did not identify any benefit. In the SRs identifying benefits, IAHA was noted to be most efficacious around eight weeks. 4,8 Prolonged effects of IAHA were (...) ? Includes evidence published from 2005-2007 ? Rec grades: A, B, C, D ? Algorithms provided ? There is some evidence that IAHA may provide some benefit for knee OA ? Algorithm: IAHA for knee OA for patients with moderate- severe persistent symptoms in whom mild- moderate strategies have ? Literature search not designed to identify safety trials; thus this guideline does not provide full safety or usage information on drug Viscosupplementation for the Treatment of Osteoarthritis of the Knee 4 Table 1

2014 Canadian Agency for Drugs and Technologies in Health - Rapid Review

359. Worsening of pain and function over 5 years in individuals with 'early' OA is related to structural damage: data from the Osteoarthritis Initiative and CHECK (Cohort Hip & Cohort Knee) study (Abstract)

Worsening of pain and function over 5 years in individuals with 'early' OA is related to structural damage: data from the Osteoarthritis Initiative and CHECK (Cohort Hip & Cohort Knee) study To analyse the relation of joint damage on evolution of pain and physical functioning in two different cohorts of early phase of osteoarthritis (OA): Osteoarthritis Initiative (OAI) and Cohort Hip & Cohort Knee study (CHECK).Longitudinal data of 4-5 years follow-up (= medium term) of CHECK study and OAI (...) were used. The Western Ontario and McMaster Universities of Osteoarthritis Index (WOMAC) was used to measure pain and physical functioning. For comparison with CHECK a subgroup of the OAI Incidence cohort was selected, Generalised estimating equations were used and all models were adjusted for gender, Body Mass Index, age, amount of working hours, racial background and hip pain at baseline. Finally, an interaction term was added to assess a possible differential effect of radiological progression

2014 EvidenceUpdates

360. Intra-articular use of hyaluronic acid in the treatment of knee osteoarthritis

the likelihood of requiring joint replacement. Most Clinical Practice Guidelines and Health Sponsors consulted agree to cover HA for knee OA which has not responded to non-pharmacological and pharmacological treatments. They do not mention if its use is covered as single or repeated doses. More studies assessing the evolution of single and repeated doses at a longer term are needed to reach better conclusions. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Hyaluronic Acids (...) Intra-articular use of hyaluronic acid in the treatment of knee osteoarthritis Acido hialurónico intra-articular para artrosis de rodilla [Intra-articular use of hyaluronic acid in the treatment of knee osteoarthritis] Acido hialurónico intra-articular para artrosis de rodilla [Intra-articular use of hyaluronic acid in the treatment of knee osteoarthritis] Pichon Riviere A, Augustovski F, Garcia Marti S, Alcaraz A, Glujovsky D, Lopez A, Rey-Ares L, Bardach A, Ciapponi A Record Status

2014 Health Technology Assessment (HTA) Database.